NASDAQ · TIL
Instil Bio, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for TIL: Nov 12, 2026
Instil Bio, Inc. Common Stock is estimated to report earnings on 11/12/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. The reported EPS for the same quarter last year was $-2.01.
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · The Motley Fool · RTTNews · Quiver Quantitative- Fintel · Apr 8, 10:56 PM EDTInstil Bio (TIL) Price Target Increased by 24.53% to 67.32The average one-year price target for Instil Bio (NasdaqCM:TIL) has been revised to $67.32 / share. This is an increase of 24.53% from the prior estimate of $54.06 dated March 25, 2026. The price target is an average of many targets provided by analysts. The l
- Fintel · Oct 29, 12:43 AM EDTInstil Bio (TIL) Price Target Increased by 41.50% to 97.66The average one-year price target for Instil Bio (NasdaqCM:TIL) has been revised to $97.66 / share. This is an increase of 41.50% from the prior estimate of $69.02 dated September 27, 2025. The price target is an average of many targets provided by analysts. T
- The Motley Fool · Aug 13, 7:09 AM EDTInstil Bio Posts Wider Loss in Q2Non-GAAP earnings per share (EPS) for Q2 2025 were $(2.88), missing expectations by 15.2% compared to the $(2.50) estimate.
- RTTNews · Jul 2, 6:14 AM EDTInstil Bio Announces Clearance Of AXN-2510 IND(RTTNews) – Instil Bio (TIL) announced the clearance of an Investigational New Drug application for AXN-2510 by the FDA. Instil expects to initiate a phase 1 trial of 2510 as monotherapy for patients with relapsed/refractory solid tumors before the end of 2025. The trial is desig
- Quiver Quantitative · Jul 2, 6:11 AM EDTInstil Bio Announces FDA Clearance for IND of AXN-2510, Phase 1 Trial Expected by End of 2025Instil Bio plans to start a phase 1 trial of AXN-2510 for solid tumors following FDA IND clearance.
- Zacks · Jun 20, 12:00 PM EDTInstil Bio, Inc. (TIL) Is Up 4.07% in One Week: What You Should KnowDoes Instil Bio, Inc. (TIL) have what it takes to be a top stock pick for momentum investors? Let's find out.
- Zacks · Jun 16, 9:55 AM EDTWall Street Analysts Think Instil Bio (TIL) Could Surge 246.68%: Read This Before Placing a BetThe mean of analysts' price targets for Instil Bio (TIL) points to a 246.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- Quiver Quantitative · Jun 11, 7:14 AM EDTInstil Bio Appoints John Maraganore, Ph.D., to Board of Axion Bio to Advance Development of AXN-2510Instil Bio appoints Dr. John Maraganore to Axion Bio's board to enhance AXN-2510's development for non-small cell lung cancer.
- Zacks · Jun 4, 12:00 PM EDTAre You Looking for a Top Momentum Pick? Why Instil Bio, Inc. (TIL) is a Great ChoiceDoes Instil Bio, Inc. (TIL) have what it takes to be a top stock pick for momentum investors? Let's find out.
- Zacks · Jun 2, 11:46 AM EDTSummit Therapeutics Stock Nosedives on Mixed NSCLC Study ResultsSMMT plunges 31% as its NSCLC drug shows strong PFS but misses statistical significance on survival data.
- Quiver Quantitative · Jun 2, 7:14 AM EDTInstil Bio, Inc. Appoints Jamie Freedman, M.D., Ph.D., as Chief Medical Officer to Propel Cancer Therapy DevelopmentInstil Bio appoints Dr. Jamie Freedman as Chief Medical Officer to advance cancer therapy AXN-2510.
- BNK Invest · May 30, 2:16 PM EDTFriday Sector Laggards: Semiconductors, Biotechnology StocksIn trading on Friday, semiconductors shares were relative laggards, down on the day by about 3%. Helping drag down the group were shares of Ambarella off about 17.3% and shares of Wolfspeed off about 8.6% on the day. Also lagging the market Friday are biotechnology shares, dow
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Instil Bio, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.